Ara
Toplam kayıt 7, listelenen: 1-7
Prognostic factors and intensive care outcome in post-transplant phase of hematopoietic stem cell transplantation intensive care outcome in hematopoietic stem cell transplantation
(Springer India, 2023)
Introduction To identify new clinical and biologic parameters associated with short-term survival in allogeneic or autologous hematopoietic stem cell transplantation (HSCT) patients who were admitted to the intensive care ...
Plerixafor in autologous stem cell transplantation: Does it affect engraftment kinetics?
(Springer Nature, 2023)
...
Plerixafor in autologous stem cell transplantation: Does it affect engraftment kinetics?
(Elsevier Ltd, 2023)
Plerixafor increases stem cell mobilization by reversibly binding to the chemokine receptor CXCR4. In our study, we examined the results of mobilization with plerixafor and granulocyte colony-stimulating factor (G-CSF) and ...
Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.
(Lippincott Williams & Wilkins, 2023)
...
Idarubicin versus daunorubicin versus mitoxantrone for induction chemotherapy in acute myeloid leukemia: Patient registration study of Turkish society of hematologyacute myeloid leukemia working group
(American Society of Hematology, 2023)
Introduction: Standard induction chemotherapy in newly diagnosed acute myeloid leukemia (AML) includes a combination of standard-dose cytarabine and an anthracycline (idarubicin [IDA], daunorubicin [DNR], or mitoxantrone ...